Interaction of Recombinant Myocilin with the Matricellular Protein SPARC: Functional Implications

José-Daniel Aroca-Aguilar,1,2 Francisco Sánchez-Sánchez,1,2 Sikha Ghosh,3 Ana Fernández-Navarro,1,2 Miguel Coca-Prados,4,5,4 and Julio Escribano6,1,2

PURPOSE. Myocilin is an extracellular glycoprotein with unknown function that is associated with glaucoma. Calpain II cleaves recombinant myocilin within the linker region of the protein, releasing the C-terminal olfactomedin domain from the N-terminal domain. The authors previously reported that myocilin interacts with the C-terminal region of hevin, a secretory glycoprotein belonging to the SPARC family of matricellular proteins. This study aims to investigate the interaction of myocilin with SPARC.

METHODS. Protein-protein interactions were evaluated by the yeast two-hybrid system. The positive interactions were confirmed by solid-phase binding assays using Ni-chelating HPLC purified recombinant proteins and coexpression of recombinant proteins in HEK-293T cells. Coexpression of myocilin, SPARC, and hevin in ocular tissues was identified by immunofluorescence microscopy, Western blot, and array-based gene profiling.

RESULTS. Yeast two-hybrid analyses showed that myocilin interacted with the highly conserved C-terminal extracellular calcium binding (EC) domain within SPARC and hevin. Solid-phase binding assays confirmed these interactions and showed that both myocilin and its C-terminal olfactomedin fragment interacted noncovalently with SPARC and a peptide containing the EC domain of SPARC. Full-length myocilin interacted with higher affinity with SPARC and its EC domain than the myocilin C-terminal fragment. Coexpression of the two recombinant proteins in HEK-293T cells also indicated their intracellular interaction.

CONCLUSIONS. Recombinant myocilin and SPARC interact through their C-terminal domains. The data suggest that the proteolytic processing of myocilin modulates this interaction as well as the interactions of myocilin with other extracellular matrix and matricellular proteins, further supporting a functional role for this proteolytic cleavage.

Myocilin, a member of the olfactomedin family of proteins, is a secreted glycoprotein with an unidentified function that is expressed in different human tissues.1–5 It forms large extracellular aggregates linked by disulfide bonds.6–8 Mutations in the MYOCILIN (MYOC) gene are involved in different types of glaucoma.9–11 This protein is organized into three modular domains, each of which is encoded by one of its three exons. Recombinant myocilin undergoes an intracellular endoproteolytic cleavage in the middle of the polypeptide chain by calpain II, releasing two fragments that contain the N- and C-terminal domains.12–15 This cleavage occurs in the endoplasmatic reticulum.16 The C-terminal fragment has been detected in both human and bovine ciliary body (CB), in aqueous humor and trabecular meshwork (TM),14–16 and in the eye angle of mice,17 indicating that this specific proteolyis also occurs in vivo.

It is believed that myocilin interactions may play key roles in the biological function of myocilin. The disulfide aggregates of this protein interact noncovalently, suggesting that myocilin complexes may organize into a reversible extracellular network sustained by noncovalentN-terminal interactions.16 It has been reported that myocilin interacts with flotillin-1, a structural protein of lipid rafts,18 as well as with extracellular proteins such as fibronectin,19 laminin,20,21 decorin,26 collagen,20 fibrillin-1,20,21 and hevin (also known as SC1 and SPARC-like 1).23 Hevin is a matricellular protein with an unclear function that modulates cell shape and cell adhesion to different substrates in vitro, including fibronectin.24 This protein belongs to the secreted protein acidic and rich in cysteine (SPARC) family of matricellular proteins. The proteins in this family also include testicans 1–3,25 SMOC-126 and 2,27 thrombospondins 1 and 2, osteopontin, and tenascins C and X.28,29 Like myocilin, they present a modular design and share homologous C-terminal domains, including extracellular Ca2+-binding (EC) and follistatin-like domains. SPARC is a multifunctional protein that modulates cellular interactions with extracellular matrix (ECM) during embryogenesis and in adult tissues that continue to remodel.25,30 Furthermore, it

From the 1Laboratorio de Genética Molecular Humana, Facultad de Medicina/Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, Albacete, Spain; 2Department of Ophthalmology and Visual Science, Yale University School of Medicine, 300 George St., Room 6100, New Haven, Connecticut; and 3Fundación de Investigación Oftalmológica, Instituto Oftalmológico de Castilla–La Mancha, Albacete, Spain; 4Department of Ophthalmology, University of Connecticut, Newington, Connecticut; and 5Departamento de Biología Celular, Universidad de Murcia, Murcia, Spain.
binds components of the ECM, affects certain growth factors, alters the expression of matrix metalloproteinases, and has counteradhesive and antiangiogenic effects.25,31,32

We investigated the interaction of myocilin with the hevin-related protein SPARC. We show that myocilin interacts through its C-terminal region with the EC domain of SPARC in a reversible fashion. Our data suggest that the specific cleavage of myocilin could modulate its interactions with SPARC and other extracellular proteins (e.g., laminin and fibronectin).

METHODS

Yeast Two-Hybrid cDNAs

Recombinant bait cDNAs encoding myocilin (lacking the signal peptide) and the C-terminal domain of myocilin (amino acids 217–504) were PCR amplified using a myocilin cDNA clone14 as a template and the primer pairs 1 to 2 and 2 to 3 (Table 1), respectively. The following PCR conditions were used in all amplifications for yeast-two hybrid constructs: annealing at 55°C for 30 seconds and extension at 72°C for 3 minutes for 35 cycles. The resulting PCR products were fused to the GAL4 DNA binding domain by cloning into the EcoRI and BamHI restriction sites of the cloning vector (pAS2.1 vector; Clontech, Palo Alto, CA). Another vector (pACT2; Clontech) was used to clone prey cDNAs encoding the C-terminal regions of SPARC (amino acids 152–303) and hevin (amino acids 509–664). These molecules were amplified from cDNAs obtained from the Full-Length Mammalian Gene Collection (Invitrogen-GIBCO, Carlsbad, CA) encoding human hevin (GenBank Accession No. NM_004684, Invitrogen, 4939390) or SPARC (GenBank Accession No. NM_003118, Invitrogen, 3529445), using the primer pairs 4–5 and 6–7, respectively (Table 1). The obtained PCR products were subcloned into the EcoRI-XhoI and BamHI-XhoI restriction sites, respectively. The recombinant plasmids encoded the different proteins fused to the GAL4 activation domain. We used pVA3–1 [BD/murine p53 (codons 72–390) fusion; Clontech], pLAM5/H11032 [BD/human laminin C (codons 66–230) fusion] and pTD1–1 [AD/SV40 large T antigen (codons 84–708) fusion; Clontech] as control cDNAs.

TABLE 1. Oligonucleotide Primers Used to Generate cDNAs Encoding Myocilin, SPARC, and Hevin cDNAs Used in Yeast Two-Hybrid Assays and to Express Recombinant Proteins in HEK-293T Cells

<table>
<thead>
<tr>
<th>Primers for Yeast Two-Hybrid Assays</th>
<th>5′→3′ Sequence</th>
<th>Restriction Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AATAAGATTCAAGAAGCTCAAGCTAGGAAAGGCC</td>
<td>EcoRI</td>
</tr>
<tr>
<td>2</td>
<td>TTAAGGGACTGAGATGGATGGATCTTCGTCGACCTGC</td>
<td>BamHI</td>
</tr>
<tr>
<td>3</td>
<td>TTTTGAATTCTTCGCTATCTCAGGAGTGG</td>
<td>EcoRI</td>
</tr>
<tr>
<td>4</td>
<td>GTGTGCTGAGCTCAAGAAGAGAGATTTTCATC</td>
<td>XhoI</td>
</tr>
<tr>
<td>5</td>
<td>AAATGAAATTCTTTAATACTTCATGTCAGG</td>
<td>EcoRI</td>
</tr>
<tr>
<td>6</td>
<td>TGTTGCTGAGTTAGTACAGAAGAGATTTTCATC</td>
<td>XhoI</td>
</tr>
<tr>
<td>7</td>
<td>GAACGACAGCTGCTTGGCAATCTGGCTGGGGG</td>
<td>BamHI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primers for Expression of Recombinant Proteins in HEK-293T Cells</th>
<th>5′→3′ Sequence</th>
<th>Restriction Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>GCCCTCTAGATGAGGCTGTCAGCTTTCCTTCTCC</td>
<td>XbaI</td>
</tr>
<tr>
<td>9</td>
<td>GCTGGAGATCCAGGATCGAAGATCTGTTCG</td>
<td>BamHI</td>
</tr>
<tr>
<td>10</td>
<td>GTTCAGAGAAAGGGGAGGGATGGCAGAGGCTGGGGG</td>
<td>—</td>
</tr>
<tr>
<td>11</td>
<td>GCCGGGAGGGCTTGGCAATCTGGCTGGAGC</td>
<td>—</td>
</tr>
</tbody>
</table>

Sequences in bold italic type indicate restriction sites introduced in primers to facilitate subcloning of PCR products.

for yeast-two hybrid constructs: annealing at 55°C for 30 seconds and extension at 72°C for 3 minutes for 35 cycles. The resulting PCR products were fused to the GAL4 DNA binding domain by cloning into the EcoRI and BamHI restriction sites of the cloning vector (pAS2.1; vector; Clontech, Palo Alto, CA). Another vector (pACT2; Clontech) was used to clone prey cDNAs encoding the C-terminal regions of SPARC (amino acids 152–303) and hevin (amino acids 509–664). These molecules were amplified from cDNAs obtained from the Full-Length Mammalian Gene Collection (Invitrogen-GIBCO, Carlsbad, CA) encoding human hevin (GenBank Accession No. NM_004684, Invitrogen, 4939390) or SPARC (GenBank Accession No. NM_003118, Invitrogen, 3529445), using the primer pairs 4–5 and 6–7, respectively (Table 1). The obtained PCR products were subcloned into the EcoRI-XhoI and BamHI-XhoI restriction sites, respectively. The recombinant plasmids encoded the different proteins fused to the GAL4 activation domain. We used pVA3–1 [BD/murine p53 (codons 72–390) fusion; Clontech], pLAM5/H11032 [BD/human laminin C (codons 66–230) fusion] and pTD1–1 [AD/SV40 large T antigen (codons 84–708) fusion; Clontech] as control cDNAs.

METHODS

Yeast Two-Hybrid cDNAs

Recombinant bait cDNAs encoding myocilin (lacking the signal peptide) and the C-terminal domain of myocilin (amino acids 217–504) were PCR amplified using a myocilin cDNA clone14 as a template and the primer pairs 1 to 2 and 2 to 3 (Table 1), respectively. The following PCR conditions were used in all amplifications for yeast-two hybrid constructs: annealing at 55°C for 30 seconds and extension at 72°C for 3 minutes for 35 cycles. The resulting PCR products were fused to the GAL4 DNA binding domain by cloning into the EcoRI and BamHI restriction sites of the cloning vector (pAS2.1; vector; Clontech, Palo Alto, CA). Another vector (pACT2; Clontech) was used to clone prey cDNAs encoding the C-terminal regions of SPARC (amino acids 152–303) and hevin (amino acids 509–664). These molecules were amplified from cDNAs obtained from the Full-Length Mammalian Gene Collection (Invitrogen-GIBCO, Carlsbad, CA) encoding human hevin (GenBank Accession No. NM_004684, Invitrogen, 4939390) or SPARC (GenBank Accession No. NM_003118, Invitrogen, 3529445), using the primer pairs 4–5 and 6–7, respectively (Table 1). The obtained PCR products were subcloned into the EcoRI-XhoI and BamHI-XhoI restriction sites, respectively. The recombinant plasmids encoded the different proteins fused to the GAL4 activation domain. We used pVA3–1 [BD/murine p53 (codons 72–390) fusion; Clontech], pLAM5/H11032 [BD/human laminin C (codons 66–230) fusion] and pTD1–1 [AD/SV40 large T antigen (codons 84–708) fusion; Clontech] as control cDNAs.

FIGURE 1. Pairwise amino acid sequence alignment of the C-terminal region of hevin and members of the BM-40/SPARC/osteonectin family of proteins. The region of hevin shown in the alignment participates in the interaction with myocilin. The amino acids identical or similar to those of hevin are highlighted with a black or gray background, respectively. The numbers on the right and on the left correspond to the amino acid positions. The location of the follistatin-like (F), Kazal-like (K), and extracellular calcium binding (EC) domains are also indicated. Pairwise sequence alignments were generated using the ClustalW program.53
TABLE 2. Amino Acid Sequence Identity and Similarity between the EC Regions of Hevin and Four Members of the BM-40/SPARC/Osteonectin Family of Proteins

<table>
<thead>
<tr>
<th>Protein</th>
<th>Identity (%)</th>
<th>Similarity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hevin (Amino Acids 432–664)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPARC (amino acids 71–303)</td>
<td>60.8</td>
<td>78.0</td>
</tr>
<tr>
<td>Testican-2 (amino acids 88–344)</td>
<td>18.1</td>
<td>48.3</td>
</tr>
<tr>
<td>Testican-3 (amino acids 85–344)</td>
<td>17.7</td>
<td>43.1</td>
</tr>
<tr>
<td>Follistatin (amino acids 93–290)</td>
<td>7.8</td>
<td>28.9</td>
</tr>
</tbody>
</table>

Values were obtained by pairwise comparisons using ClustalW software.55

Yeast Two-Hybrid Analysis

Protein-protein interaction analyses with the yeast two-hybrid assay were performed (Matchmaker-3 kit; Clontech). Saccharomyces cerevisiae CG1945 was cotransformed with the corresponding bait and prey recombinant plasmids following the manufacturer’s recommendations (Clontech). For auxotrophic assays cotransformed clones were plated on selection medium (Ade/His/Leu/Tryp/X-gal) and incubated at 30°C for 8–21 days. For β-galactosidase assay expression assays were lysed by three freeze-thaw cycles in liquid nitrogen. The enzymatic activity was determined using the lysates and ONPG (ortho-nitrophenyl-β-D-galactopyranoside) as a chromogenic substrate (Sigma-Aldrich, St. Louis, MO), according to the manufacturer’s instructions (Clontech). These assays were performed in triplicate.

Expression and Purification of Recombinant Proteins

The cDNAs encoding the different versions of recombinant myocilin and hevin, cloned in the pcDNA3.1 vector, were obtained as previously described.12,14,22 The cDNAs encoding SPARC and its EC domain were PCR amplified using the aforementioned SPARC cDNA clone as a template, and the primers pairs 8–9 (annealing at 50°C for 30 seconds, extension 90 seconds) and 9–10 (annealing at 50°C for 30 seconds, extension 90 seconds; Table 1), respectively. The signal peptide of SPARC was obtained by PCR using the primer pair 8–11 (annealing at 50°C for 30 seconds, extension for 30 seconds) and 9–10 (annealing at 50°C for 30 seconds, extension 90 seconds; Table 1), respectively. The cDNAs encoding the different versions of recombinant myocilin were PCR amplified using the aforementioned SPARC cDNA clone as a template, and the primer pairs 8–9 (annealing at 50°C for 30 seconds, extension 90 seconds; Table 1) and the primer pairs 8–11 (annealing at 50°C for 30 seconds, extension 90 seconds for 35 cycles; Table 1) and fused to the 5′ end of the EC domain as described previously.12 Recombinant proteins were transiently expressed in human embryonic kidney 293T (HEK-293T) cells bought from the American Type Culture Collection. These cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% fetal bovine serum as described previously.12,14 The recombinant proteins were directly purified from conditioned culture media by Ni-chelating high-performance liquid chromatography (HPLC).16 The purity of isolated proteins was assessed by SDS-PAGE with silver nitrate staining.55 The identity of the isolated recombinant proteins was confirmed by Western blot analyses using either anti-myc or anti-HA antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).12,14

Solid-Phase Binding Assays

Microtiter wells (Microtest plate 96-well flat bottom; Sarstedt, Nürnberg, Germany) were incubated with 50 μL of the different purified recombinant proteins, fibronectin, laminin, or decorin (all Sigma) [0.1 μM protein in coating buffer (50 mM NaCO3, pH 9.6)] for 12 hours at 4°C.10 The protein in the coating buffer was substituted for with BSA (Sigma) as a control for nonspecific binding. Wells were blocked for 3 hours with 200 μL of 10% BSA in coating buffer at 4°C. After washing 3 times with tris buffered saline (TBS)-TWEEN (25 mM tris-glycine, pH 7.5, 150 mM NaCl, 1% Tween-20), increasing concentrations (0–2.5 μM) of purified recombinant myocilin and its C-terminal fragment fused to the myc epitope at their C-terminal ends, dissolved in 50 μL of TBS-TWEEN containing 5% BSA, were added to each well and incubated for 2 hours under gentle agitation (100 rpm) at room temperature. Competitive binding analyses were performed by incubating increasing amounts of recombinant myocilin-Ct-HA (0.05–2 μM) to immobilized SPARC-EC in the presence of myocilin-EC myc (competitor) at four myocilin-Ct-myc/myocilin-Ct-HA molar ratios (0, 0.5/1, 1/1, and 2/1). The competitive binding of myocilin-HA to immobilized SPARC-EC was tested at one concentration of myocilin-HA (0.1 μM) in the presence of myocilin-myc (competitor) at the aforementioned molar ratios. We also analyzed the competitive interaction of myocilin-Ct-HA with SPARC-EC in the presence of myocilin-myc (competitor) at myocilin-myc/myocilin-Ct-HA molar ratios of 0, 1/1, and 2/1. Wells were incubated with an anti-myc antibody, diluted at 1:500, for 2 hours at room temperature. A horseradish peroxidase-conjugated antibody against mouse IgG (Pierce, Rockford, IL) was diluted at 1:500. Colorimetric detection and protein concentration were determined in triplicate independent assays as described previously.16

Data were statistically analyzed with commercial software (SigmaStat 2.0; SPSS, Chicago, IL).

Coexpression of Myocilin and SPARC in HEK-293T Cells

To test the intracellular interaction of myocilin and SPARC, HEK-293T cells were transiently cotransfected with a SPARC-myc cDNA (200 ng) and increasing amounts (0–400 ng) of a second cDNA encoding myocilin-HA using reagent (SuperFect Transfection Reagent; Qiagen, Valencia, CA). In parallel control assays, SPARC-myc cDNA (200 ng) was cotransfected with increasing amounts (0–400 ng) of a cDNA encoding IGF-BP1-Myc, also cloned in the pcDNA3.1 vector. The total cDNA (400 ng) was kept constant in all transfections by adding the required amount of nonrecombinant cDNA (pcDNA3.1). Forty-eight hours after transfection the culture medium (CM) and the intracellular soluble (IC) fraction of cell lysates were collected.15,34 Similar amounts of proteins, quantified by the Bradford assay, were transferred to nitrocellulose membranes and detected using either anti-myc (1:400 dilution) or anti-HA (1:3000 dilution) antibodies.

![Figure 2](http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932967/)
formed with plasmids pTD1–1-AD (AD/SV40 large T antigen fusion) and pVA3–1BD (BD/murine p53 fusion) or pTD1–1-AD and pLAM5–1-BD (BD/human laminin C fusion), respectively. The results are the mean ± SE of triplicate assays. AD, GAL4 activation domain; BD, GAL4 DNA binding domain.

Using an anti-LDH antibody (AB-1222. Chemicon, diluted 1:5000), we verified by Western blot that similar amounts of protein were analyzed in the IC fractions (data not shown). Luminescent imaging film (LAS3000-mini; Fujiﬁlm, Tokyo, Japan) was used for chemiluminescence detection. Proteins were quantiﬁed by densitometry in triplicated independent assays as described previously.14,54

Immunofluorescence Microscopy

For immunofluorescence analyses, semi-thin cryostat sections (0.5–1.0 μm thick) from bovine ciliary processes were used as previously described.56 The following antisera were tested: (1) an anti-peptide (R14T) antibody to myocilin;2 (2) a commercial SPARC/osteonectin antibody (AON-5031; Hematologic Technologies, Essex Junction, VT); and (3) an antibody to SCI/hevin.57 Tissue sections were incubated at 37°C for 90 minutes with the above-mentioned primary antibodies (1:100). They were then rinsed in PBS and further incubated with the secondary antisera (100-fold– diluted rhodamine- conjugated goat anti-rabbit IgG) for 60 minutes After washing in PBS and mounting in a solution of glycerol mounting medium, the specimens were analyzed with a fluorescent microscope (Axioskop; Carl Zeiss, Göttingen, Germany). Photographs were taken using high-speed ﬁlm (TMAX-400; Eastman Kodak, Rochester, NY). As a control, sections were stained with secondary antibodies alone or with BSA or normal serum.

Gene Expression Proﬁling Analysis

Total RNA was isolated from distinct human ocular tissues using reagent (TRizol; Invitrogen) according to the manufacturer’s instructions. The ocular tissues were dissected from a pair of eyes of a 57-year-old donor (cadaver), obtained through the National Disease Research Interchange (Philadelphia, PA). The procedures conformed to the tenets of the Declaration of Helsinki. The RNA samples were further puriﬁed using cleanup columns (Qiagen RNaseasy; Qiagen, Hilden, Germany). cRNA labeling and hybridization to the chip and array data analysis were carried out by the Yale Neuroscience Microarray Center (NIH Neuroscience Microarray Consortium) at the Keck Foundation at Yale University. The quality of RNA was determined with a bioanalyzer gel, and samples with an OD 260/280 > 1.8 were further processed for gene expression proﬁling (Illumina platform; Illumina, San Diego, CA). Single- and double-stranded cDNAs were synthesized and puriﬁed using an ampliﬁcation kit beadchip (Illumina Total/Prep RNA; Illumina). An in vitro transcription reaction was then carried out in the presence of biotinylated UTP and CTP to produce biotin-labeled cRNA from the double-stranded cDNA and was then hybridized (beadchip HumanHT-12; Illumina), stained with streptavidin-Cy3, and the array was scanned (BeadArray reader; Illumina) and images were analyzed (Beadstudio software; Illumina). Quality control and data analyses were carried out according to the instructions provided by Illumina. Signals corresponding to myocilin SPARC and hevin were selected for the analysis.

RESULTS

We have previously reported that myocilin interacts with the C-terminal region of hevin, which contains the follistatin, Kazal-like, and EC domains (amino acids 401–664).23 This region is highly conserved in the BM-40/SPARC/osteonectin family (Fig. 1). Interestingly, hevin shows the highest sequence similarity with SPARC (60.8% amino acid identity; 78% similarity; Fig. 1 and Table 2). These facts prompted us to initially test the possible interaction of SPARC with myocilin using the yeast two-hybrid system. To achieve this goal, we generated two sets of fusion proteins. The first set was composed of full-length myocilin and its C-terminal half (myocilin-Ct, amino acids 233–
504), which resembles the fragment resulting from the proteolytic processing of the full-length protein by calpain II (Fig. 2A). The two myocilin versions were fused to the GAL4 DNA binding domain (Fig. 2A). The second set consisted of hybrids between sequences encoding the GAL4 DNA activation domain and the C-terminal EC domain of either SPARC (AD-SPARC-EC, amino acids 152–303) or hevin (AD-hevin-EC, amino acids 510–664; Fig. 2A). Histidine prototrophy was observed in yeast cotransformed with fusion plasmids encoding myocilin and either SPARC-EC or hevin-EC, as well as in yeast coexpressing myocilin-Ct and the C-terminal regions of SPARC or hevin (Fig. 3A). Histidine prototrophy was also detected in the positive control (pTD1–1-AD/pVA3–1BD cotransformation; Fig. 3A). As expected, yeast cotransformed with plasmids pTD1–1-AD and pLAM5–1-BD (negative control; Fig. 3A) was unable to grow in medium lacking His.

Two-hybrid interactions were initially verified and quantified, comparing their relative strength by measuring β-galactosidase activity in liquid yeast culture. In accordance with the previous assay, recombinant myocilin and its C-terminal fragment interacted with the C-terminal fragment of SPARC. The intensity of the interactions of the two

**FIGURE 5.** Analysis of myocilin-SPARC interactions by solid-phase binding assays. Binding of recombinant myocilin-HA (▲) and myocilin-Ct-HA (●) to either SPARC-myc (A) or the EC domain of SPARC-myc (B) immobilized in 96-well microtiter plates. The interaction of the two versions of myocilin with hevin-myc (C), the C-terminal region of hevin-myc (D), fibronectin (E), laminin (F), and decorin (G) was also tested. As a negative control of the assay recombinant myocilin was added to BSA-blocked wells, which did not contain any other immobilized protein (H). The bound proteins were detected using an anti-HA antibody. The data shown in (H) represent the background (baseline) binding of the two versions of recombinant myocilin in all the interaction assays, which for simplicity is included only in this panel. Values in all graphs correspond to total binding. Error bars represent the SE of triplicate experiments.
The identity of the proteins C-terminal ends (Fig. 2B) and were purified by Ni-chelating HPLC as described previously.16 The identity of the proteins Kazal-like domains (hevin-Ct-myc). In addition, all the recombinant proteins were tagged with a 6xHis tail at their most C-terminal ends (Fig. 2B). The C-terminal SPARC polypeptide corresponded to the EC domain (SPARC-EC-myc), whereas that of hevin also incorporated the follistatin- and Kazal-like domains (hevin-Ct-myc). In addition, all the recombinant proteins were tagged with a 6xHis tail at their most C-terminal ends (Fig. 2B) and were purified by Ni-chelating HPLC as described previously.16 The identity of the proteins obtained was confirmed by Western blot analysis (Fig. 4A), and their purity, estimated by silver staining, was generally, higher than 80% (Fig. 4B). Recombinant hevin was not stained by silver nitrate because of its low concentration.

To further confirm the interaction between myocilin and other proteins from solid-phase binding assays shown in Figures 5 and 6, we carried out solid-phase binding assays using the purified recombinant proteins expressed in HEK-293T cells. Myocilin and its C-terminal fragment were expressed as recombinant proteins fused to the HA epitope at their C-terminal ends (Fig. 2B, myocilin-Ct-HA). The recombinant myocilin C-terminal fragment generated for these assays also coincided with the polypeptide produced by the proteolytic processing of the protein (amino acids 217–504). SPARC, hevin, and their respective C-terminal fragments incorporated the myc epitope at their C-terminal ends (Fig. 2B). The C-terminal SPARC polypeptide corresponded to the EC domain (SPARC-EC-myc), whereas that of hevin also incorporated the follistatin- and Kazal-like domains (hevin-Ct-myc). In addition, all the recombinant proteins were tagged with a 6xHis tail at their most C-terminal ends (Fig. 2B) and were purified by Ni-chelating HPLC as described previously.16

### Solid-Phase Binding Assays

To further confirm the interaction between myocilin and SPARC we carried out solid-phase binding assays using the purified recombinant proteins expressed in HEK-293T cells. Myocilin and its C-terminal fragment were expressed as recombinant proteins fused to the HA epitope at their C-terminal ends (Fig. 2B, myocilin-Ct-HA). The recombinant myocilin C-terminal fragment generated for these assays also coincided with the polypeptide produced by the proteolytic processing of the protein (amino acids 217–504). SPARC, hevin, and their respective C-terminal fragments incorporated the myc epitope at their C-terminal ends (Fig. 2B). The C-terminal SPARC polypeptide corresponded to the EC domain (SPARC-EC-myc), whereas that of hevin also incorporated the follistatin- and Kazal-like domains (hevin-Ct-myc). In addition, all the recombinant proteins were tagged with a 6xHis tail at their most C-terminal ends (Fig. 2B) and were purified by Ni-chelating HPLC as described previously.16

The apparent affinities of the interactions were estimated as the amount of protein required for half-maximal binding ($1/2B_{\text{max}}$; Table 3). The affinity of noncovalent binding of myocilin to SPARC and hevin was of a similar order of magnitude to that of the myocilin-myocilin interactions ($1/2B_{\text{max}}$ ranging from 1.1 to 6.7; Table 3). Myocilin-Ct-HA showed reduced interaction affinity with SPARC, hevin, and the C-terminal fragments of these two proteins ($1/2B_{\text{max}}$ ranging from 19.4 to 38.2 pmol; Table 3). These data corroborate the noncovalent interaction between myocilin and SPARC and support that it is mediated by the olfactomedin and EC domains of these proteins. In addition, they indicate that the C-terminal fragment of myocilin interacts in a positive cooperative fashion, and with reduced affinity, with both SPARC and hevin as well as with the C-terminal fragments of these two matricellular proteins. The positive cooperativity was also suggested by rough estimates of Hill coefficients obtained from the slope of Hill plots, which clearly exceeded 1. We are aware that the experimental design followed is not well suited to derive reliable Hill coefficients. Further analyses are required to confirm this point.

As an additional positive control, the interaction of myocilin with two ECM proteins, fibronectin and laminin, which have been shown to interact with it,19–21 was also analyzed by

---

**Table 3.** Estimation of the Affinities ($1/2B_{\text{max}}$) of the Interactions between Myocilin and Other Proteins from Solid-Phase Binding Assays Shown in Figures 5 and 6.

<table>
<thead>
<tr>
<th>Interaction</th>
<th>$1/2B_{\text{max}}$ (pmol)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Myocilin vs.</strong></td>
<td></td>
</tr>
<tr>
<td>Hevin</td>
<td>6.7</td>
</tr>
<tr>
<td>Hevin-Ct</td>
<td>4.9</td>
</tr>
<tr>
<td>SPARC</td>
<td>1.1</td>
</tr>
<tr>
<td>SPARC-EC</td>
<td>2.5</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>9.5</td>
</tr>
<tr>
<td>Laminin</td>
<td>4.4</td>
</tr>
<tr>
<td>Myocilin*</td>
<td>5.2</td>
</tr>
<tr>
<td><strong>Myocilin-Ct vs.</strong></td>
<td></td>
</tr>
<tr>
<td>Hevin</td>
<td>38.2</td>
</tr>
<tr>
<td>Hevin-Ct</td>
<td>31.4</td>
</tr>
<tr>
<td>SPARC</td>
<td>19.4</td>
</tr>
<tr>
<td>SPARC-EC</td>
<td>24.1</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>12.1</td>
</tr>
<tr>
<td>Laminin</td>
<td>8.8</td>
</tr>
</tbody>
</table>

$1/2B_{\text{max}}$ represents the amount of protein required for half-maximal binding.

* Estimated from published data.16

---

**Figure 6.** Competitive binding of recombinant myocilin to immobilized SPARC-EC. (A) Binding of recombinant myocilin-Ct-HA to immobilized SPARC-EC in the presence of myocilin-Ct-myc (competitor) at myocilin-Ct-myc/myocilin-Ct-HA molar ratios of $0/k$, $0.5/k$, $1.0/k$, $1.0/k$, and $2.0/k$. The insert shows the competitive binding of myocilin-HA (0.1 μM) to immobilized SPARC-EC in the presence of myocilin-myc (competitor) at the three molar ratios indicated above. (B) Binding of myocilin-Ct-HA to SPARC-EC in the presence of myocilin-myc (competitor) at myocilin-myc/myocilin-Ct-HA molar ratios of $0/k$, $1.0/k$, and $2.0/k$. 

---

Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932967/ on 06/24/2017
solid-phase binding assays. Myocilin and its C-terminal fragment interacted noncovalently with the two proteins in a manner similar to that described for SPARC and hevin (Figs. 5E, 5F). The estimated binding affinities of myocilin to fibronectin (9.5 pmol) and laminin (4.4 pmol) were in the same range observed for the interactions of myocilin with SPARC and hevin (Table 3). Myocilin-Ct-myc also showed reduced affinity of myocilin to immobilized SPARC-EC in the presence of myocilin-HA (competitor) at four different myocilin-Ct-myc/myocilin-Ct-HA molar ratios (0, 0.5/1, 1/1, and 2/1; Fig. 6A). The competitive binding of myocilin-HA to immobilized SPARC-EC was tested only at one myocilin-HA concentration (0.1 μM) in the presence of myocilin-myc (competitor) at the aforementioned molar ratios. We observed that the two competitors decreased the binding of the two versions of recombinant myocilin to immobilized SPARC-EC in a dose-dependent manner (Fig. 6A). Myocilin-yc also displaced binding of myocilin-Ct-HA to SPARC-EC (Fig. 6B). These data support the specificity of the interactions.

**Coexpression of Recombinant Myocilin and SPARC in HEK-293T Cells**

Previous evidence indicates that myocilin and hevin interact intracellularly in the secretory pathway. We reasoned that a similar interaction could occur between myocilin and SPARC. To test this hypothesis, we analyzed the intracellular behavior of a constant amount of SPARC-myc coexpressed with increasing amounts of myocilin-HA in HEK-293T cells (Fig. 7). SPARC-myc accumulated intracellularly (from 5% to 15%) as the amount of recombinant myocilin-HA increased in the intracellular fraction (Figs. 7A and 7C). However, intracellular SPARC-myc remained constant at 5% when it was coexpressed with increasing amounts of IGF-BP1-Myc, a recombinant protein used as control (Figs. 7B and 7D). These data indicate that the two proteins interact intracellularly in the secretory pathway.

**Coexpression of Myocilin, SPARC, and Hevin in Ocular Tissues**

The coexpression of myocilin, SPARC, and hevin in ocular tissues was investigated by immunofluorescence, Western blot, and microarray gene profiling. The immunofluorescence of semi-thin frozen sections of bovine ciliary processes using antibodies against myocilin, SPARC, or hevin showed a clear labeling of the NPE layer with the three antibodies (Fig. 8). The abundance of melanin in the PE does not enable us to completely rule out the presence of three proteins in this layer.

Western blot analysis revealed the presence of the three proteins in the bovine aqueous humor (Fig. 9). According to previous reports, the anti-myocilin RI4T antibody recognized a band with an apparent slightly higher molecular weight than that of the recombinant human protein. The SPARC antibody detected a polypeptide of approximately 43 kDa in the aqueous humor. Recombinant SPARC, which contained the myc and HA epitopes, had a somewhat higher molecular weight than the bovine protein. Finally, bovine hevin was detected as a doublet of around 118 kDa, which was close to the molecular weight of the recombinant human protein which also carried the two epitopes. In addition, the gene expression profiling for myocilin, SPARC, and hevin among the human ocular tissues was determined by microarray analysis and showed that SPARC and hevin were expressed in all the tissues. However, these genes were coexpressed abundantly with myocilin, predominantly in the TM and iris and CB (Fig. 10).

**DISCUSSION**

The biological function of myocilin has remained elusive for more than a decade. As an approach to address this question, different groups have attempted to identify proteins that interact with myocilin.

We have previously reported that myocilin interacts with the C-terminal region of hevin, a member of the SPARC family of matricellular proteins. Among the members of this family, the C-terminal region of hevin and SPARC share the highest sequence similarity (60.8%). Based on these facts, we reasoned that myocilin may also interact with SPARC. The
interaction between the C-terminal regions of the two proteins was initially evidenced by the two-hybrid assay and was further supported by the solid-phase binding assays using purified recombinant proteins and the coexpression in HEK-293T cells. The relative interactions in yeast, estimated by liquid β-galactosidase activity measurements, indicate that the binding of the myocilin C-terminal fragment to the C-terminal fragments of SPARC and hevin apparently increases with respect to the entire myocilin. In contrast, the solid-phase binding assays indicate that full-length myocilin exhibits higher affinities than myocilin-Ct in the interaction with SPARC or hevin. This discrepancy can be explained if we bear in mind that there is not direct correlation between β-galactosidase activity and the Kd of an interaction. In fact, in the yeast two-hybrid system, the tested interactions possibly depend on factors such as the orientation of the fused protein and

**Figure 8.** Cellular distribution of myocilin, SPARC, and hevin in the bovine ocular ciliary epithelium. Cryostat sections of bovine ciliary processes were stained with polyclonal antibodies to myocilin (A, B), SPARC (C, D), and hevin (E, F). The immunolabeling of these proteins is confined preferentially along the nonpigmented cell layer of the ciliary epithelium. The strong presence of melanin granules in the pigmented cells masked a possible presence of these proteins in this cell layer. In the presence of normal serum or in the absence of the primary antibody no significant label was detected (G, H). NPE, nonpigmented epithelium; PE, pigmented epithelium. (B), (D), (F), and (H) are phase contrast micrographs of (A), (C), (E), and (G), respectively. Magnification: (A–F) ×600; (G–H) ×400.
either the GAL-4 activation or the binding domains, the reporter gene used, or the expression levels of the two-hybrid proteins. The minimal C-terminal SPARC fragment that interacted with myocilin contained the EC domain, thus revealing that it is involved in the interaction with the olfactomedin domain of myocilin. It is also worth noting that the C-terminal fragment of myocilin used in all binding assays coincides with that resulting after the proteolytic processing of the protein by calpain II. Therefore, the differential binding properties of full-length myocilin and its C-terminal fragment suggest that the specific cleavage of myocilin might regulate its interaction with the matricellular proteins SPARC and hevin, as well as with the ECM proteins fibronectin and laminin, as has been reported for myocilin self-aggregation. The typical saturable hyperbolic curves of the interaction of myocilin with the two versions of both SPARC and hevin, as well as with fibronectin and laminin, suggest the absence of cooperativity. This is in contrast with the sigmoidal binding of the myocilin C-terminal fragment to the same proteins, indicating the possible existence of more than one binding site and positive cooperativity. This type of cooperativity may be due to interactions between the binding sites or to the existence of different binding constants. The C-terminal fragment of myocilin also showed increased maximal binding compared with full-length myocilin. This may be due to its smaller molecular size because it is able to interact with a higher number of binding sites. Overall, these data reveal the interaction of myocilin with SPARC through their C-terminal regions and further support the previously reported interaction with hevin. On the other hand, the specific intracellular accumulation of SPARC, which correlates with the amount of myocilin coexpressed in HEK-293T cells, indicates the existence of an interaction between the two recombinant proteins early in the secretory pathway.

Our data also show that myocilin, SPARC, and hevin are coexpressed in different ocular tissues, which is a condition required for the in vivo interaction of these molecules. However, additional experiments are required to demonstrate that the interactions among these molecules actually occur in vivo. In accordance with these results, it has been reported that SPARC is present with myocilin in ocular tissues such as the trabecular meshwork, aqueous humor and vitreous, non-pigmented epithelial cells, and the smooth muscle of the ciliary body.

We previously proposed that extracellular myocilin may form a dynamic molecular network composed of disulfide aggregates that are linked in a reversible way by noncovalent interactions through the N-terminal domain of myocilin (Fig. 11A). The data presented herein allow the completion of this model. We hypothesize that the molecular myocilin network may also bind noncovalently, through the C-terminal domain of myocilin monomers, with the EC domains of both SPARC and hevin (Fig. 11A). Furthermore, the myocilin network can also interact with fibronectin and laminin in the ECM, acting as a linker between matricellular and ECM proteins. These features resemble those of matricellular proteins, a functional group of nonhomologous and secreted proteins that mediate the interactions between cells and the extracellular matrix. Thus, we also speculate that myocilin might function as a putative matricellular protein. This issue has also been discussed previously.

There are interesting functional parallelisms between myocilin, SPARC, and hevin related to cell adhesion and proteolytic processing. Along these lines, hevin and SPARC exhibit a strong antiadhesive activity toward attachment of endothelial cells to fibronectin in vitro, as well as antisprouting and focal adhesion-labilizing activity. Similarly, myocilin blocks the adhesion of cultured TM cells onto fibronectin and induces the loss of actin stress fibers and focal adhesions, but it promotes substrate adhesion, spreading, and formation of focal contacts in podocytes and mesangial cells. Regarding the proteolytic processing of these proteins, a 29 kDa N-terminal SPARC fragment has been detected in both human and bovine ocular tissues, including the ciliary body and aqueous humor. In addition, hevin is present in different mouse tissues, including the eye, as a 55-kDa fragment that probably contains the C-terminal FS-EC domains. Finally, a C-terminal hevin peptide has also been detected in Engelbreth-Holm-Swarm murine sarcoma cells, which may also occur for tissue-derived SPARC. Altogether, these data suggest that the three pro-
extracellular matrix (ECM) proteins fibronectin (F) and laminin (L). This model suggests that the extracellular and dynamic molecular network of myocilin links the ECM with matricellular proteins such as SPARC and hevin in a reversible fashion. (B) Activation of the intracellular proteolytic processing of myocilin reduces the myocilin network. The released C-terminal fragment interacts with SPARC and hevin with lower affinity than full-length myocilin. The extracellular presence of the N-terminal fragment decreases because it is mainly retained intracellularly.12 Modified with permission from Aroca-Aguilar JD, Martinez-Redondo F, Sanchez-Sanchez F, Coca-Prados M, Escribano J. Functional role of proteolytic processing of recombinant myocilin in self-aggregation. Invest Ophthalmol Vis Sci. 2010;51:72–78.


Reference


